Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:0
članak: 7 od 16  
Back povratak na rezultate
Vojnosanitetski pregled
2015, vol. 72, br. 12, str. 1085-1092
jezik rada: engleski
vrsta rada: originalan članak
doi:10.2298/vsp140526016s
Efekat antipsihotika na nespecifične markere inflamacije u prvoj epizodi shizofrenije
aClinic for Psychiatric Disorders 'Dr Laza Lazarević', Belgrade
bUniverzitet u Kragujevcu, Medicinski fakultet
cClinic for Psychiatric Disorders 'Dr Laza Lazarević', Belgrade + Faculty of Medical Sciences, Kragujevac
dUniverzitet u Beogradu, Medicinski fakultet, Institut za medicinsku statistiku i informatiku

e-adresa: vesnastef@open.telekom.rs

Sažetak

Uvod/Cilj. U razmatranju još uvek nepoznate etiologije shizofrenije, disfunkcija imunskog sistema koja uključuje i inflamaciju zauzima značajno mesto. Cilj našeg rada bio je da se odrede koncentracije nespecifičnih markera zapaljenja u krvi, u prvoj epizodi shizofrenije i njihova povezanost sa terapijskim odgovorom na antipsihotike. Metode. U radu smo određivali koncentracije nespecifičnih markera zapaljenja u krvi: leukocita (WBC), C-reaktivnog proteina (CRP), sedimentacije eritrocita (SE) i elemenata leukocitarne formule: granulocita (Gra), limfocita (Lym) i monocita (Mon), i to u prvoj epizodi šizofrenije, kod 78 hospitalizovanih bolesnika u Klinici za psihijatrijske bolesti 'Dr Laza Lazarević' u Beogradu. Njihove koncentracije određivali smo pri prijemu i četiri sedmice nakon antipsihotičke terapije. Težinu psihopatologije i farmakoterapijski odgovor pratili smo primenom Skale pozitivnih i negativnih sindroma shizofrenije (Positive and negative syndrome scale for schizophrenia - PANSS). Rezultati. U prvoj epizodi shizofrenije, pre uvođenja antipsihotika, postojala je visoka učestalost abnormalnih laboratorijskih vrednosti (≥ 25% bolesnika) sledećih nespecifičnih markera inflamacije: WBC, CRP i SE, kao i Gra u leukocitarnoj formuli, ali i smanjenje svih njih nakon četiri sedmice antipsihotičke terapije, na nivou visoke statističke značajnosti za WBC i Gra (p < 0.001). Sedimentacija eritrocita ostala je povećana kod čak 50% bolesnika i nakon 4- sedmičnog antipsihotičkog lečenja, na nivou statističke značajnosti kod onih koji nisu reagovali na terapiju u odnosu na one koji jesu (p = 0.045 ). Zaključak. Dobijeni rezultati pokazuju da u prvoj epizodi shizofrenije kod subpopulacije bolesnika postoje povećane vrednosti nespecifičnih markera inflamacije u krvi (WBC, CRP , SE i Gra iz leukocitarne formule), sa tendencijom njihove normalizacije nakon četiri sedmice antipsihotičkog tretmana.

Ključne reči

Reference

Bergink, V., Gibney, S.M., Drexhage, H.A. (2014) Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biological Psychiatry, 75(4): 324-31
Bessis, A., Béchade, C., Bernard, D., Roumier, A. (2007) Microglial control of neuronal death and synaptic properties. Glia, 55(3): 233-8
Blasco-Fontecilla, H., Baca-Garcia, E., de Leon, J. (2010) Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade. Schizophrenia Research, 119(1-3): 160-163
Borovcanin, M., Jovanovic, I., Radosavljevic, G., Djukic, D.S., Stefanovic, V., Arsenijevic, N., Lukic, M.L. (2013) Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophrenia research, 147(1): 103-9
Dean, B. (2011) Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. international journal of neuropsychopharmacology, 14(7): 997-1012
Dickerson, F., Stallings, C., Origoni, A., Boronow, J., Yolken, R. (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophrenia Research, 93(1-3): 261-265
Dickerson, F., Stallings, C., Origoni, A., Vaughan, C., Khushalani, S., Yang, S., Yolken, R. (2013) C-reactive protein is elevated in schizophrenia. Schizophrenia research, 143(1): 198-202
Dimitrov, D.H. (2011) Correlation or coincidence between monocytosis and worsening of psychotic symptoms in veterans with schizophrenia?. Schizophrenia Research, 126(1-3): 306-307
Drzyzga, L., Obuchowicz, E., Marcinowska, A., Herman, Z.S. (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain, behavior, and immunity, 20(6): 532-45
Dunjic-Kostic, B., Jasovic-Gasic, M., Ivkovic, M., Radonjic, N.V., Pantovic, M., Damjanovic, A., Totic-Poznanovic, S., Jovanovic, A., Nikolic, T., Petronijevic, N.D. (2013) Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatria Danubina, 25(1): 55-61
Fan, X., Liu, E.Y., Freudenreich, O., Park, J.H., Liu, D., Wang, J., Yi, Z., Goff, D., Henderson, D.C. (2010) Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophrenia Research, 118(1-3): 211-217
Fan, X., Pristach, C., Liu, E.Y., Freudenreich, O., Henderson, D.C., Goff, D.C. (2007) Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Research, 149(1-3): 267-271
Keller, W.R., Kum, L.M., Wehring, H.J., Koola, M.M., Buchanan, R.W., Kelly, D.L. (2013) A review of anti-inflammatory agents for symptoms of schizophrenia. Journal of Psychopharmacology, 27(4): 337-42
Kelly, D.L., Conley, R.R., Love, R.C., Morrison, J.A., Mcmahon, R.P. (2008) Metabolic Risk with Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-Week Trial of Risperidone and Olanzapine. Annals of Clinical Psychiatry, 20(2): 71-78
Leucht, S., Davis, J.M., Engel, R.R., Kane, J.M., Wagenpfeil, S. (2007) Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology, 32(9): 1903-10
Li, J., Baud, O., Vartanian, T., Volpe, J.J., Rosenberg, P.A. (2005) Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proceedings of the National Academy of Sciences of the United States of America, 102(28): 9936-41
Melamed, Y., Sirota, P. (2000) Erythrocyte sedimentation rate in patients with schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 45(10): 938
Meyer, U. (2011) Anti-inflammatory signaling in schizophrenia. Brain, behavior, and immunity, 25(8): 1507-18
Miller, B.J., Gassama, B., Sebastian, D., Buckley, P., Mellor, A. (2013) Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biological Psychiatry, 73(10): 993-9
Miller, B.J., Mellor, A., Buckley, P. (2013) Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain, Behavior, and Immunity, 31: 82-89
Miller, C.L., Llenos, I.C., Dulay, J.R., Barillo, M.M., Yolken, R.H., Weis, S. (2004) Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiology of disease, 15(3): 618-29
Mitchell, A.J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., de Hert, M. (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophrenia bulletin, 39(2): 306-18
Monji, A., Kato, T., Kanba, S. (2009) Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry and clinical neurosciences, 63(3): 257-65
Müller, N., Myint, A.M., Krause, D., Weidinger, E., Schwarz, M.J. (2013) Antiinflammatory treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 5(42); 146-53
Na, K.S., Jung, H.Y., Kim, Y.K. (2014) The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 48: 277-86
Na, K., Kim, W., Jung, H., Ryu, S.G., Min, K.J., Park, K., Kim, Y., Yoon, J., Ahn, Y.M., Kim, C. (2012) Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 39(2): 295-300
Nagai, T., Ibi, D., Yamada, K. (2011) Animal model for schizophrenia that reflects gene-environment interactions. Biological & pharmaceutical bulletin, 34(9): 1364-8
Nitta, M., Kishimoto, T., Müller, N., Weiser, M., Davidson, M., Kane, J.M., Correll, C.U. (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophrenia bulletin, 39(6): 1230-41
Pavlović, M., Babić, D., Rastović, P., Ljevak, I. (2013) Association of erythrocyte sedimentation rate and fibrinogen concentration with metabolic syndrome in a schizophrenic patients. Psychiatr Danub, 25(Suppl 1): 51-5
Peet, M. (2006) The metabolic syndrome, omega-3 fatty acids and inflammatory processes in relation to schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids, 75(4-5): 323-327
Roberts, R.C., Roche, J.K., Conley, R.R. (2005) Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis. Synapse, 56(4): 185-97
Sommer, I.E., van Westrhenen, R., Begemann, M.J.H., de Witte, L.D., Leucht, S., Kahn, R.S. (2013) Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update. Schizophrenia Bulletin, 40(1): 181-191
Sperner-Unterweger, B., Whitworth, A., Kemmler, G., Hilbe, W., Thaler, J., Weiss, G., Fleischhacker, W.W. (1999) T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophrenia research, 38(1): 61-70
Steiner, J., Gos, T., Bogerts, B., Bielau, H., Drexhage, H.A., Bernstein, H. (2013) Possible impact of microglial cells and the monocyte-macrophage system on suicidal behavior. CNS & neurological disorders drug targets, 12(7): 971-9
Stellwagen, D., Malenka, R.C. (2006) Synaptic scaling mediated by glial TNF-alpha. Nature, 440(7087): 1054-9
Suvisaari, J., Mantere, O. (2013) Inflammation theories in psychotic disorders: a critical review. Infectious disorders drug targets, 13(1): 59-70
Thomas, S.P., Nandhra, H.S., Singh, S.P. (2012) Pharmacologic treatment of first-episode schizophrenia: A review of the literature. Prim Care Companion CNS Disord, 14(1); 11, pii: PCC. r01198
Zorrilla, E.P., Cannon, T.D., Gur, R.E., Kessler, J. (1996) Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease?. Biological Psychiatry, 40(9): 825-33